Cargando…

Testicular recurrence of oligometastatic prostatic adenocarcinoma after 22 years of androgen deprivation therapy

Testicular metastasis of carcinoma is a rare condition. We report a rare case of right testicular metastasis of prostatic adenocarcinoma in an 84 years old patient, after more than 20 years of controlled disease under androgen deprivation therapy. Follow-up consisted in PSA monitoring, clinical exam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fortier, Alexa, Mokadem, Seif, Cornet, Emlyn, Cornu, Jean-Nicolas, Sabourin, Jean-Christophe, Pfister, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058943/ https://www.ncbi.nlm.nih.gov/pubmed/35509726 http://dx.doi.org/10.1016/j.eucr.2022.102055

Ejemplares similares

Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone
por: Mistretta, Francesco A., et al.
Publicado: (2022)

Lacrimal sac adenocarcinoma managed with androgen deprivation
por: Abramson, David H., et al.
Publicado: (2020)

Androgen deprivation therapy prevents bladder cancer recurrence
por: Izumi, Koji, et al.
Publicado: (2014)

Lacrimal gland adenocarcinoma responding to checkpoint inhibition and androgen deprivation
por: Bulbul, Ajaz
Publicado: (2018)

Segmental testicular infarction: A case report of a rare condition
por: Saidani, Bilel, et al.
Publicado: (2022)

Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial
por: Zhao, Xianzhi, et al.
Publicado: (2022)

Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer
por: Saxby, Helen, et al.
Publicado: (2022)

Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread
por: Batich, Kristen A., et al.
Publicado: (2019)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
por: Deijen, Charlotte L., et al.
Publicado: (2021)

Solitary Leptomeningeal Recurrence From Prostate Adenocarcinoma After Treatment With Cytotoxic Gene Therapy, Radiation Therapy, and Androgen Deprivation Therapy
por: Chevli, Neil, et al.
Publicado: (2021)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Recalcitrant Paraneoplastic Pemphigus Associated With Prostate Adenocarcinoma: Spectacular Evolution Under Androgen Deprivation
por: Moata, Hajar, et al.
Publicado: (2023)

Oligometastatic recurrence of an oesophageal adenocarcinoma at a chest drain site following radical treatment: palliative treatment or resection?
por: Wen, David, et al.
Publicado: (2018)

Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach
por: Jung, Jin-On, et al.
Publicado: (2020)

Oligometastatic Adenocarcinoma of the Esophagus: Current Understanding, Diagnosis, and Therapeutic Strategies
por: Rogers, Michael P., et al.
Publicado: (2021)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Neoplasias testiculares /
por: Rodríguez Fortier, Maricela
Publicado: (1994)

Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
por: Sun, Qi, et al.
Publicado: (2023)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease
por: Stahl, John M, et al.
Publicado: (2017)

Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence
por: Izumi, Koji, et al.
Publicado: (2016)

Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer
por: Gomez, Daniel R., et al.
Publicado: (2012)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma
por: Feng, Xiao-Yao, et al.
Publicado: (2022)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival
por: Yarchoan, Mark, et al.
Publicado: (2015)

Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors
por: Franceschini, Davide, et al.
Publicado: (2023)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Brachytherapy for oligometastatic prostate cancer to the penis
por: Martz, Nicolas, et al.
Publicado: (2021)

Inflammatory suppurated tumor of urachus mimicking a malignant urachus adenocarcinoma
por: Chebbi, Sami, et al.
Publicado: (2023)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation therapy increases brain ageing
por: Plata-Bello, Julio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hn2a1l6aiufg4qadifmfvlvim9